Stay updated with breaking news from Yukiko Kimura. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The annual meeting of the American College of Rheumatology was held this year from Nov. 10 to 14 in Philadelphia and attracted participants from around the world, including rheumatology specialists, physicians, scientists, and other health professionals. The conference featured presentations focusing on the latest advances in the diagnosis and treatment of arthritis as well as
Three-year outcome data from the STOP-JIA study showed that early methotrexate plus a biologic may aid remission and disease inactivity in pediatric polyarticular juvenile idiopathic arthritis.
New research presented this week at ACR Convergence, the American College of Rheumatology's annual meeting, found that patients started on early, aggressive treatment with a combination of biologic and conventional disease modifying antirheumatic drugs (DMARDs) achieved clinically inactive disease in children with polyarticular juvenile idiopathic arthritis (JIA) more frequently compared to other treatment plans 24 months after starting treatment.